2022--provirex--hamburg-researchers-want-to-be-able-to-cure-hiv-soon---magazine--healty-and-sport-news

Unlike CRISPR-Cas9, which creates double-strand breaks and relies on error-prone cellular repair, Brec1 performs a concerted "cut and paste" action that is inherently error-free.

Research published in Nature Biotechnology demonstrated that Brec1 can target and excise over 90% of clinical HIV-1 isolates found globally. If ART is stopped, this latent reservoir reactivates,

While modern ART allows people living with HIV (PLWH) to lead near-normal lives, it cannot eliminate the "provirus"—the viral DNA that integrates into the host's own genome. If ART is stopped, this latent reservoir reactivates, leading to viral rebound. A permanent cure requires the physical removal or permanent silencing of this integrated DNA. Joachim Hauber

The core of Hamburg’s research is , developed through directed molecular evolution by teams led by Prof. Joachim Hauber. If ART is stopped

Building upon the research conducted by and the University Medical Center Hamburg-Eppendorf (UKE) , this paper outlines the scientific and strategic progress made toward a functional HIV cure as of late 2022. Abstract